Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin | Zendy

H Nathan | Zendy; Sandra A N Walker | Zendy; Marion Elligsen | Zendy; Alex Kiss | Zendy; Lesley Palmay | Zendy; Grace Ho | Zendy; Jeff Powis | Zendy; Vikas Bansal | Zendy; Jerome A. Leis | Zendy

Open Access

Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin

Author(s) -

H Nathan,

Sandra A N Walker,

Marion Elligsen,

Alex Kiss,

Lesley Palmay,

Grace Ho,

Jeff Powis,

Vikas Bansal,

Jerome A. Leis

Publication year - 2019

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkz531

Subject(s) - medicine , nephrotoxicity , vancomycin , dosing , rifle , odds ratio , retrospective cohort study , renal function , confounding , cohort , surgery , anesthesia , toxicity , history , archaeology , biology , bacteria , genetics , staphylococcus aureus

Patients with good renal function receiving intermittent-infusion vancomycin (IIV) may require total daily doses ≥4 g to achieve trough concentrations of 15-20 mg/L, increasing the risk of vancomycin-associated nephrotoxicity. Continuous-infusion vancomycin (CIV) may be associated with a lower risk of vancomycin-associated nephrotoxicity compared with IIV, but studies comparing safety of both dosing strategies are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research